The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia
10.3760/cma.j.issn.0578-1426.2011.01.014
- VernacularTitle:HAA方案诱导治疗成人初发急性髓系白血病150例疗效观察
- Author:
Yanping SONG
;
Yin TONG
;
Wenbin QIAN
;
Wenyuan MAI
;
Haitao MENG
;
Jijing QIAN
;
Hongyan TONG
;
Jian HUANG
;
Liping MAO
;
Weilai XU
;
Jie JIN
- Publication Type:Journal Article
- Keywords:
Leukemia,myelocytic,acute;
Harringtonines;
Drug therapy,combination
- From:
Chinese Journal of Internal Medicine
2011;50(1):48-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of HAA regimen (homoharringtonine,cytarabine and aclarubicin) in the treatment of 150 newly diagnosed adult acute myeloid leukemia (AML).Methods All patients entered the study from May 1999 to June 2008 were treated with HAA regimen. Coxsurvival analysis was used to estimate the survival rate and differences between M1/M2 and M4/M5 were compared with 2-sided log-rank test. Results Out of the 150 patients, 121 (81%) achieved complete remission (CR). After the first course, CR rate was 68%. The CR rates of 97%, 84% and 38% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For the patients with CR, the median follow-up time was 16.5 ( 1.5-100.5 ) months, and the estimated 3-year survival rate was 45%. The estimated 3-year relapse free survival rate was 52% for the 121 patients with CR.Conclusions HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be achieved with only one or two courses.
